Investigation of Efficacy and Tolerability of Levetiracetam for Epilepsy in Elderly
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 137
- 试验地点
- 1
- 主要终点
- Seizure free rate
研究概览
简要总结
This prospective interventional study was conducted between 2023 and 2025 at the Department of Neurology of Bouali Sina Hospital. Consecutive elderly patients presenting with epilepsy were screened for eligibility. The diagnosis of epilepsy was confirmed by the treating neurologist. The patients underwent treatment with levetiracetam. Primary and secondary outcomes were investigated as was explained before.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥60 years
- •Diagnosis of epilepsy
排除标准
- •Chronic kidney disease requiring dialysis
- •History of psychotic disorders or current use of anxiolytic, antidepressant, or antipsychotic medications
- •Current use of antiseizure medications for any reason
研究组 & 干预措施
Levetiracetam
Elderly patients with epilepsy who have received levetiracetam
干预措施: Oral levetiracetam (Drug)
结局指标
主要结局
Seizure free rate
时间窗: 12 months
The rate of patients who stayed seizure-free after drug initiation
Retention rate
时间窗: 12 months
The rate of patients who continue taking drug
Time to first seizure
时间窗: at occurrence of first seizure
The interval between starting drug and recurrence of seizure
Time to withdrawal
时间窗: the day that the patient stops taking drug
The interval between starting drug and stoping its use
次要结局
- Tolerability rate(12 months)
研究者
Nasim Tabrizi
Associate professor of neurology
Mazandaran University of Medical Sciences